Answers are grounded in this paper and cite their sources.
Adrenocorticotropic hormone 1–24 (ACTH[1–24]) has a similar effect as endogenous ACTH(1–39) to generate cortisol by targeting the MC2R receptor on the adrenal gland. A new investigational ACTH receptor antagonist drug is being developed to treat diseases of ACTH excess (e.g., Cushing's disease) by binding to the MC2R receptor. Administration of ACTH(1–24) was used in a Phase I clinical study to assess the ability of this drug candidate to suppress the cortisol response to ACTH stimulation. A hybrid immunoaffinity-LCMS assay measuring ACTH(1–24) with a concentration range of 10 to 400 pg/ml was developed to support the study. Consistent and acceptable A&P results were achieved. The assay development and qualification will be discussed.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: